<DOC>
	<DOCNO>NCT01111968</DOCNO>
	<brief_summary>This prospective phase I study evaluate safety , tolerability immunogenicity nine adjuvanted candidate vaccine pandemic influenza A ( H1N1 ) virus .</brief_summary>
	<brief_title>Evaluation Pandemic Influenza A ( H1N1 ) Candidate Vaccines</brief_title>
	<detailed_description>The candidate vaccine produce Butantan institute - Sao Paulo , Brazil</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Health adult gender Age ≥ 18 ≤ 50 year Able understand every required study procedure Female volunteer agree take acceptable contraceptive method Menopause characterize absence menstrual flux two consective year Normal value prestablished laboratory assay Accpetance participate sign consent form Any chronic condition Be immunossupressive stimulant therapy Have egg alergy Have past history alergy sazonal influenza vaccine Have receive another inactivated vaccine within prior 2 week live vaccine past four week his/her participation study Acute infectious disease seven day prior vaccination Female breasthfeeding Confirmed prior infection pandemic influenza A Participation another clinical trial last 6 month Any condition identify principal investigator consider safe enrollment volunteer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>vaccine</keyword>
	<keyword>pandemic influenza A</keyword>
	<keyword>adjuvant</keyword>
	<keyword>safety</keyword>
</DOC>